 | Up a level |
Wu, Yi-Long and Guarneri, Valentina and Voon, Pei Jye and Lim, Boon Khaw and Yang, Jin-Ji and Wislez, Marie and Huang, Cheng and Liam, Chong Kin and Mazieres, Julien and Tho, Lye Mun and Hayashi, Hidetoshi and Nhung, Nguyen Viet and Chia, Puey Ling and de Marinis, Filippo and Raskin, Jo and Zhou, Qinghua and Finocchiaro, Giovanna and Le, Anh Tuan and Wang, Jialei and Dooms, Christophe and Kato, Terufumi and Nadal, Ernest and Hin, How Soon and Smit, Egbert F. and Wermke, Martin and Tan, Daniel and Morise, Masahiro and O'Brate, Aurora and Adrian, Svenja and Pfeiffer, Boris M. and Stroh, Christopher and Juraeva, Dilafruz and Strotmann, Rainer and Goteti, Kosalaram and Berghoff, Karin and Ellers-Lenz, Barbara and Karachaliou, Niki and Le, Xiuning and Kim, Tae Min and INSIGHT investigators, - (2024) Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncology, 25 (8). pp. 989-1002. ISSN 1470-2045, DOI https://doi.org/10.1016/S1470-2045(24)00270-5.
